Bionomics IPO Presentation Deck

Ongoing Strategic Collaboration with Merck & Co. MSD Collaboration Overview Development Updates Bionomics - Entered into in 2014 to develop a7 receptor PAMS targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions Merck funds all R&D activities including clinical development and WW commercialization of any products from collaboration Milestone payments of US$20M upfront and US$10M in 2017 when 1st compound entered Phase 1 clinical trials Eligible to receive up to US$465M in additional development and commercial milestone payments plus royalties Includes 2 candidates which are PAMs of the a7 receptor in early-stage Phase 1 safety and biomarker clinical trials for treating cognitive impairment The 1st compound has completed Phase 1 safety clinical trials in healthy subjects and there are ongoing plans for further biomarker studies In 2020, a second molecule that showed an improved potency profile in preclinical animal models was advanced by Merck into Phase 1 clinical trials MERCK PARTNERSHIP Snapshot of Early BNC375 Studies Recognition (%) 80- 60- 40- Veh Wang et al. J Pharmacol Exp Ther 373:311-324, May 2020 https://pubmed.ncbi.nlm.nih.gov/3.2094.294/ PAM- Positive alosteric modulator MSD - A trødename of Merck & Co., Inc, Kenilworth NY USA Scopolamine (1mpk, IP) -- 0.01 0.1 1 10 Don BNC375 (mg/kg, PO) % Correct Difficult Trials 100- 60- 40- 20 V 0 Scopolamine***** 0.1 BNC375 1 ng/kg, PO) 10 100- % correct Difficult Trials 50- BNC 375 (mg/kg, IM) 24

View entire presentation